Advice

Following a full submission.

Risperidone is accepted for use within NHS Scotland for the treatment of episodes of mania in bipolar disorder.

Risperidone has similar efficacy to haloperidol in improving symptom scores, with fewer extrapyramidal side effects. In an economic model based on indirect comparison, monotherapy with risperidone appears to be cost-effective. No evidence is submitted on its cost-effectiveness profile in co-therapy.

Download detailed advice27KB (PDF)

Download

Medicine details

Medicine name:
Risperidone (Risperdal®)
SMC ID:
113/04
Indication:
Mania in bipolar disorder
Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Central nervous system
Submission type
Full
Status
Accepted
Date advice published
09 August 2004